MedPath

Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials

Not Applicable
Recruiting
Conditions
Cognitive Disorders
Interventions
Biological: Blood samples
Other: Interviewing the subject and scales
Other: Neurocognitive evaluation
Other: Taste tests
Other: Computerized food preference questionnaires
Other: Nutritional status - body composition
Registration Number
NCT05888961
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

The aim of the MAPEG 2 study is to explore gustatory function and to follow its evolution in the 5 following groups of participants:

* Healthy subjects

* Participants with isolated cognitive complaint

* Participants with minor neurocognitive disorder

* Participants with mild Alzheimer-type major neurocognitive disorders

* Participants with moderate Alzheimer-type major neurocognitive disorders

For this purpose, we want to compare the results of the following tests:

* Subjective taste tests (tasting solutions, answering food preference questionnaires),

* Gustatory evoked potential (GEP) parameters, recorded by electrodes placed on the scalp,

* And nutritional parameters (hormones of food intake by blood test, measurement of the global body composition).

Identifying and following the evolution of early taste disorders in case of cognitive disorders could improve the diagnosis of Alzheimer's disease in two ways:

* To allow an early diagnosis of Alzheimer's disease, and thus improve its management,

* To define groups of subjects at risk of developing Alzheimer's disease in later years.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
125
Inclusion Criteria
  • Person who has given oral consent.
  • For patients with mild to moderate Alzheimer's disease, the primary caregiver and the patient will be asked to provide oral consent
  • Person of legal age
  • Body Mass Index (BMI) < 30 kg/m².
  • For the healthy group: absence of cognitive complaints and normal neurological assessment
  • Patients meeting the criteria for isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation
  • Patients meeting diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5
  • Patients meeting diagnostic criteria for mild Alzheimer's disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers), MMSE score ≥ 20 and CDR score of 1 or 1.5
  • Patients meeting diagnostic criteria for moderate Alzheimer's disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological workup, CSF biomarkers), MMSE score 15≤ 20, and CDR score of 1.5 or 2
  • Fasting for at least 2 hours before GEP measurement
Exclusion Criteria
  • MMSE score<15
  • Known COVID-19 infection within 6 months prior to inclusion
  • Person not affiliated to national health insurance system
  • Person under a legal protection measure (curatorship, guardianship)
  • Person subject to a measure of legal protection
  • Pregnant, parturient or breastfeeding women
  • Subjects with a pacemaker (contraindication to bioelectrical impedance measurement)
  • Adult unable to express consent or to perform cognitive tests.
  • Active smoker (> 4 cigarettes per day on a regular basis)
  • Diabetic subject (type 1 or type 2)
  • Subject with acute or chronic ENT disease
  • Treatment interfering with gustation
  • Brain MRI showing another cause of neurocognitive disorder (except for vascular lesions Fazekas 1 accepted)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control subjectsBlood samples-
Control subjectsInterviewing the subject and scales-
Control subjectsNeurocognitive evaluation-
Control subjectsTaste tests-
Control subjectsComputerized food preference questionnaires-
Control subjectsNutritional status - body composition-
Subjects with an isolated cognitive complaintBlood samples-
Subjects with an isolated cognitive complaintInterviewing the subject and scales-
Subjects with an isolated cognitive complaintNeurocognitive evaluation-
Subjects with an isolated cognitive complaintTaste tests-
Subjects with an isolated cognitive complaintComputerized food preference questionnaires-
Subjects with an isolated cognitive complaintNutritional status - body composition-
Subjects with minor neurocognitive disordersBlood samples-
Subjects with minor neurocognitive disordersInterviewing the subject and scales-
Subjects with minor neurocognitive disordersNeurocognitive evaluation-
Subjects with minor neurocognitive disordersTaste tests-
Subjects with minor neurocognitive disordersComputerized food preference questionnaires-
Subjects with minor neurocognitive disordersNutritional status - body composition-
Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease typeBlood samples-
Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease typeInterviewing the subject and scales-
Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease typeNeurocognitive evaluation-
Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease typeTaste tests-
Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease typeComputerized food preference questionnaires-
Subjects with major neurocognitive disorders of the mild to moderate Alzheimer's disease typeNutritional status - body composition-
Primary Outcome Measures
NameTimeMethod
Gustatory evoked potentials latencyAfter a 2-hour fasting period
Amplitude of the gustatory evoked potentialsAfter a 2-hour fasting period
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Dijon Bourgogne

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath